The regulatory environment for tirzepatide has changed substantially since the FDA confirmed that the tirzepatide injection drug shortage has been resolved. This development comes as MEDVi, a telehealth platform based in Newark, Delaware, continues to provide access to GLP-1 weight loss medications.
MEDVi offers compounded GLP-1 injections starting at $179 for the first month, with refills priced at $299 per month. Additionally, the oral option for compounded GLP-1 tablets is available for $249 per month, while the branded Ozempic injection is listed at $1,999 monthly.
Matthew Gallagher, the founder of MEDVi, noted the rapid growth of the company, stating, “Growth was insane.” In 2025, MEDVi achieved $401 million in sales and is projected to reach $1.8 billion in 2026. Gallagher’s strategic use of AI tools and partnerships has contributed to this success.
MEDVi’s program includes a conditional refund policy for weight loss after a minimum commitment of five months, with Gallagher emphasizing that “the body takes time to acclimate to GLP-1 medication.” The evaluating clinician retains the decision to prescribe, ensuring a tailored approach to patient care.
As MEDVi continues to expand its customer base, which grew from 300 in its first month to 1,300 in the second month, the company is well-positioned to capitalize on the resolved drug shortage and the increasing demand for weight loss solutions.
Observers expect that MEDVi’s innovative approach and competitive pricing will attract more customers seeking effective weight loss treatments. The company operates under MEDVi, LLC, located at 131 Continental Dr, Ste 305, Newark, DE 19713.
